Literature DB >> 14575886

Different regulation of adenylyl cyclase and rolipram-sensitive phosphodiesterase activity on the frontal cortex and hippocampus in learned helplessness rats.

Tetsuji Itoh1, Kohji Abe, Miwa Tokumura, Masahito Horiuchi, Osamu Inoue, Nobuhiro Ibii.   

Abstract

The present study examined the activities of adenylyl cyclase (AC) and rolipram-sensitive phosphodiesterase (PDE4) on brain regions in learned helplessness rat in order to clarify the cyclic AMP (cAMP) regulation system in the depressive state. Rats exposed to inescapable footshocks once a day for 3 days exhibited a significant increase in escape failure on Day 1 (the day after the last inescapable shock day) and Day 7. The plasma corticosterone level in rats subjected to inescapable shocks was significantly higher than that of nonstressed control rats on Days 1 and 7. The PDE4 activity of the frontal cortex was significantly lower than that of nonstressed control rats on Day 1. However, on Day 7, the PDE4 and [3H]-rolipram binding activities were significantly increased in the frontal cortex and hippocampus of learned helplessness rats compared with those of nonstressed control rats. Forskolin-stimulated AC activity was significantly decreased in the frontal cortex, hippocampus and striatum of learned helplessness rats on Day 1, but not on Day 7. Thus, a decrease in both AC and PDE4 activities was noted in the acute depressive state. In contrast, increase of PDE4 activity was noted in the delayed depressive phase, although no change of AC activity was observed. Gel shift assays also showed the decrease of cAMP-response element (CRE)-binding activity relating to cAMP activity in the frontal cortex and hippocampus of learned helplessness rats on Days 1 and 7. These findings indicated a delayed increase in PDE4 activity leading to hypofunction of the cAMP-dependent signal transduction system in the frontal cortex and hippocampus of learned helplessness rats, suggesting that up-regulation of the cAMP-degradation system by PDE4 may play a pivotal role in pathological states of chronic depression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14575886     DOI: 10.1016/j.brainres.2003.08.007

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  5 in total

1.  Repeated shock stress facilitates basolateral amygdala synaptic plasticity through decreased cAMP-specific phosphodiesterase type IV (PDE4) expression.

Authors:  Steve Ryan; Chenchen Li; Aurélie Menigoz; Rimi Hazra; Joanna Dabrowska; David Ehrlich; Katelyn Gordon; Donald G Rainnie
Journal:  Brain Struct Funct       Date:  2017-12-04       Impact factor: 3.270

2.  Effects of zaprinast and rolipram on olfactory and visual memory in the social transmission of food preference and novel object recognition tests in mice.

Authors:  Furuzan Akar; Oguz Mutlu; Ipek K Celikyurt; Emine Bektas; Mehmet H Tanyeri; Guner Ulak; Pelin Tanyeri; Faruk Erden
Journal:  Drug Target Insights       Date:  2014-04-29

3.  Antidepressant- and anxiolytic-like effects of the phosphodiesterase-4 inhibitor rolipram on behavior depend on cyclic AMP response element binding protein-mediated neurogenesis in the hippocampus.

Authors:  Yun-Feng Li; Ying Huang; Simon L Amsdell; Lan Xiao; James M O'Donnell; Han-Ting Zhang
Journal:  Neuropsychopharmacology       Date:  2009-06-10       Impact factor: 7.853

4.  Neurokinin-1 (NK-1) receptor and brain-derived neurotrophic factor (BDNF) gene expression is differentially modulated in the rat spinal dorsal horn and hippocampus during inflammatory pain.

Authors:  Vanja Duric; Kenneth E McCarson
Journal:  Mol Pain       Date:  2007-10-31       Impact factor: 3.395

5.  Zaprinast and rolipram enhances spatial and emotional memory in the elevated plus maze and passive avoidance tests and diminishes exploratory activity in naive mice.

Authors:  Furuzan Akar; Oguz Mutlu; Ipek Komsuoglu Celikyurt; Guner Ulak; Faruk Erden; Emine Bektas; Pelin Tanyeri
Journal:  Med Sci Monit Basic Res       Date:  2014-07-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.